Kidney Week Educational Symposia-Real-World Management of Hyperkalemia in Cardiorenal Patients

Video Transcription

Video Summary

The transcript captures an educational symposium on real‑world management of hyperkalemia in cardiorenal patients. Moderator Joshua Ryan introduces the topic, briefly reviews the history and nomenclature of potassium (the “K” symbol tracing to “kalium”), and presents two speakers: Paul Welling (basic science of potassium regulation) and Shav Kovesdy (clinical management).<br /><br />Welling explains how the kidney maintains tight extracellular potassium despite wide dietary variation, using gut “feed‑forward,” circadian “predictive,” and feedback control systems. He reviews potassium secretion in distal nephron principal cells via ROMK and flow‑activated BK channels, driven by ENaC‑mediated lumen negativity. He highlights newer concepts: (1) aldosterone’s action depends on mineralocorticoid receptor plus 11βHSD2 distribution, with glucocorticoids constitutively activating earlier segments; (2) dietary potassium directly upregulates ENaC and ROMK trafficking, making kidney cells potassium sensors; (3) alkali (non‑reabsorbable anion) loads stimulate potassium excretion, including an electroneutral K‑bicarbonate pathway in intercalated cells; (4) distal flow and sodium delivery strongly modulate secretion; and (5) a “potassium switch” in the DCT regulates NCC, altering downstream sodium delivery and thus kaliuresis, integrating potassium status with angiotensin II signaling.<br /><br />Kovesdy reviews guideline-driven importance of angiotensin and aldosterone system inhibition (ACEi/ARB/ARNI, MRAs including finerenone) in CKD, diabetes, and HFrEF, yet shows real‑world underuse—especially with advanced CKD—largely due to hyperkalemia and AKI concerns. He summarizes hyperkalemia risks with combination therapies, structured monitoring protocols from finerenone trials, and evidence that newer potassium binders (patiromer; SZC) can reduce hyperkalemia and enable continued RAAS/MRA therapy. He notes SGLT2 inhibitors may also lower hyperkalemia risk. Q&A emphasizes that mild hyperkalemia outcome links are largely observational, and hard outcome trials for binders are still limited.

Asset Subtitle

Moderator(s): Joshua Rein

Presentation(s):

Introduction - Joshua Rein
Advances in the Regulation of Potassium Homeostasis by RAAS and Other Hormonal Factors - Paul Welling
Updated Management of Chronic Hyperkalemia in Cardiorenal Patients: A Practical Approach - Csaba Kovesdy

Support is provided by an educational grant from CSL Vifor.

Meta Tag

Date 11/2/2023

Pathway 1 Fluid Electrolyte and Acid-Base Disorders

Pathway 2 CKD Non-Dialysis

Session ID 470169

Session Type ES - Educational Symposium

Keywords

hyperkalemia management

cardiorenal patients

potassium homeostasis

distal nephron potassium secretion

ROMK and BK channels

ENaC activity

aldosterone MR and 11βHSD2

DCT potassium switch (NCC)

RAAS inhibitors and MRAs (finerenone)

potassium binders (patiromer, SZC)